AndroBioSys
Biotechnology company that focuses on the development of novel treatments for prostate disease.
Launch date
Employees
Market cap
-
Enterprise valuation
€2—3m (Dealroom.co estimates Jan 2009.)
New York City New York (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$500k | Seed | ||
$1m | Grant | ||
$748k | Grant | ||
Total Funding | €2.0m |
Related Content
Recent News about AndroBioSys
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.